diclofenac potassium tablets / Generic mfg. - LARVOL DELTA

Eco-Conscious RP-HPLC Method for Concurrent Quantification of Assay and Dissolution Testing of Methocarbamol and Diclofenac Potassium in Tablet Formulations. (PubMed, Int J Anal Chem) - "Sustainability was assessed using the Analytical Eco-Scale, Environmental and Practical Performance Index (EPPI), and Click Analytical Chemistry Index (CACI). The method achieved an Eco-Scale score of 91, classifying it as an excellent green method, an EPPI score of 97.9, and a CACI score of 80, confirming its efficiency and practicality for routine quality control."

Journal • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain (clinicaltrials.gov) - P=N/A | N=124 | Completed | Sponsor: Cairo University | Recruiting ➔ Completed

Trial completion • Anesthesia • Dental Disorders • Pain

DITH-II/VER: A Study Comparing the Efficacy and Tolerability of a Combination of Diclofenac and Thiocolchicoside Versus Diclofenac Monotherapy in Patients with Low Back Pain. (clinicaltrialsregister.eu) - P2/3 | N=110 | Not yet recruiting | Sponsor: Verisfield Single Member S.A.

Head-to-Head • Monotherapy • New P2/3 trial • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

DI-OR-PA: A Study Comparing the Efficacy and Tolerability of a Triple Combination of Diclofenac, Orphenadrine and Paracetamol Versus Diclofenac Monotherapy and the Orphenadrine-Paracetamol Combination in Patients with Low Back Pain. (clinicaltrialsregister.eu) - P2/3 | N=224 | Not yet recruiting | Sponsor: Verisfield Single Member S.A.

Head-to-Head • Monotherapy • New P2/3 trial • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Emory University | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Cairo University | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Anesthesia • Dental Disorders • Pain

Assessment of Different Medications in Modifying the Efficacy of Anesthesia in Mandibular Molars With Acute Irreversible Pulpitis (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Ain Shams University

New P4 trial • Anesthesia • Dental Disorders

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Impact of antioxidant addition on drug dissolution: Implications for NDSRI mitigation biowaivers. (PubMed, Int J Pharm) - "This study investigates the impact of added antioxidants on dissolution of diclofenac potassium tablets...Meanwhile, due to coning, all tablets using caffeic acid, fumaric acid, or sodium ascorbate slowed dissolution in USF SIF and sodium bicarbonate buffer, except formulation B tablets with antioxidant sodium ascorbate. Overall, results point towards the feasibility of added antioxidant to not impact dissolution."

Journal

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Cairo University | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2024 ➔ Oct 2025 | Trial primary completion date: Jul 2024 ➔ Aug 2025

Enrollment open • Trial completion date • Trial primary completion date • Anesthesia • Dental Disorders • Pain

IUCD Insertion in Patients Delivered by Cesarean Section (clinicaltrials.gov) - P=N/A | N=128 | Completed | Sponsor: Al-Azhar University

New trial • Long-acting Reversible Contraceptives

Introducing a passively targeted formulation of diclofenac potassium for application in endodontics to minimize renal and gastrointestinal side effects. (PubMed, Int J Pharm) - "The introduced 25 mg DP bioadhesive disc formulation F3 was then clinically compared with the marketed 50 mg oral Cataflam® tablets regarding the effect of single-dose pretreatment in endodontic procedures of subjects with symptomatic irreversible pulpitis (SIP) through a randomized clinical trial. No significant difference was detected in all evaluated clinical criteria. This proves clinical efficiency with the advantage of half-dose administration and targeted localized effect leading to minimized renal and gastrointestinal side effects."

Adverse events • Clinical • Journal • Dental Disorders • Gastrointestinal Disorder • Nephrology

Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Emory University

Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Novel Approach of Polyvinyl Alcohol/Acrylic Acid Based Hydrogels for Controlled Delivery of Diclofenac Sodium. (PubMed, Curr Pharm Biotechnol) - "The results indicated that prepared PVA/AA hydrogels can be used as an alternative approach for the controlled delivery of diclofenac sodium."

Journal • Pain

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: Cairo University

New trial • Anesthesia • Dental Disorders • Pain

Usefulness of the BioGIT system in screening for differences in early exposure in the fasted state on an a priori basis. (PubMed, Int J Pharm) - "BioGIT experiments were performed with four APIs: Compound Α (tablet, three dose levels), Compound E (capsule PiC1, capsule PiC2 and tablet), fenofibrate (Lipidil® capsule and Lipidil 145 ONE® tablet) and Compound F (HP-β-CD aqueous solution and tablet)...The log-transformed ratios of mean BioGIT AUC values for two doses and/or two formulations estimated in this study and in a recent study for two diclofenac potassium products (Cataflam® tablet and Voltfast® sachet, same dose) vs. the corresponding log-transformed ratios of mean plasma AUC values (n=7 pairs of ratios), were included in a previously established correlation between log-transformed ratios of mean BioGIT AUC values and log-transformed ratios of plasma AUC values (n=9 pairs of ratios).The correlation between log-transformed plasma AUC ratios vs. log-transformed BioGIT AUC ratios was confirmed (n=16 pairs of ratios, R=0.90). Compared with the previously established correlation the..."

Journal

"@GSK sponsor me with Cataflam Pro please" (,@lucascaamano)

"Vai na fé, qq coisa pede publi pro Cataflam @GSK" (,@lipiatra)

Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium), in Healthy Subjects Under Fasting Condition (clinicaltrials.gov) - P1/2; N=36; Completed; Sponsor: Pharmactive Ilac Sanayi ve Tic A.S.

Clinical • New P1/2 trial • Pain

"A triste realidade de quem tenta se manter jovial mas ciático não deixa... Galera do @GSK manda uns Cataflam na humildade..." (,@HugoParabucano)

Fabrication and In Vitro Evaluation of pH-Sensitive Polymeric Hydrogels as Controlled Release Carriers. (PubMed, Gels) - "The percent drug release of the developed system and commercially available product cataflam was compared and high controlled release of the drug from the developed system was observed at both low and high pH. The mechanism of drug release from the hydrogels followed Korsmeyer-Peppas model. Conclusively, the current research work demonstrated that the prepared hydrogel could be considered as a suitable candidate for controlled delivery of diclofenac sodium."

Journal • Preclinical

"@Novartis I'm looking for cataflam 50mg in Chile, could you tell me who sell it? I beg you please, it's the medicine my mother use for her pains, I searched at the 3 most important brands: Salcobrand, ahumada and Cruz verder pharmacies, it is out of stock." (,@leo_evs)

Pain

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - P4; N=0; Withdrawn; Sponsor: Northumbria Healthcare NHS Foundation Trust; N=20 ➔ 0; Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

"Cataflam sen bi mucizesin 💊 @Novartis" (,@qxqxqxqq)

Pharmaceutical quality of seven brands of diclofenac tablet on the Saudi market. (PubMed, BMC Res Notes) - "Here, we assess the quality of reference (R1) and four generic (G1-G4) brands of 50 mg immediate-release diclofenac potassium tablet and of reference (R2) and generic (G5) brands of 100 mg sustained-release diclofenac sodium tablet...R2 and G5 did not disintegrate or dissolve in 0.1 N HCl for 2 h, disintegrated in buffer (pH 6.8) in 01:58-02:15 h: minutes, and fulfilled dissolution criteria (pH 7.5) for both United States Pharmacopoeia test-1 and test-2. Thus all seven brands met pre-specified quality criteria."

Journal